ASX Announcement

3 June 2024

200th patient is treated with the OncoSil™ device

The OncoSil™ device continues to penetrate its addressable markets, with the 200th patient treatment using this unique medical technology occurring at a Royal Adelaide Hospital in Australia

Key Highlights

- ✓ The OncoSil™ device, a single-use brachytherapy device used in the treatment of people with unresectable locally advanced pancreatic cancer, recently achieved a significant milestone, with its 200th patient treatment.
- ✓ This treatment occurred at the Royal Adelaide Hospital in Adelaide, Australia.
- ✓ The commercialisation and affirmation of the unique OncoSil™ device continues, with patient onboarding occurring in key studies and regulatory approvals being advanced.

Sydney, Australia – 3 June 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** ("**OncoSil**" or "**the Company**") is pleased to announce that 200 patients have now been treated with the OncoSil™ device.

This milestone treatment was undertaken at the Royal Adelaide Hospital in Adelaide, Australia.

The OncoSil™ device continues to penetrate its target markets

The OncoSil™ device, a single-use brachytherapy device, used to deliver a predetermined dose of beta radiation directly into cancerous tissue, recently clocked up its 200th patient treatment. The device is implanted directly into a pancreatic tumour via injection under endoscopic ultrasound guidance.

The location of the achievement of treating the 200th patient is noteworthy. This treatment was conducted at the Royal Adelaide Hospital, renowned for its extensive experience with the OncoSil™ device. Achieving this at such a prestigious institution underscores the hospital's leading role in the medical community and its commitment to advancing healthcare standards.

The treatment comes as the device continues to be endorsed as the first material advance in the treatment for patients with unresectable locally advanced pancreatic cancer in many decades.

Patient onboarding in important studies targeting further evidence of the OncoSil™ device's effectiveness, including the TRIPP-FFX and PANCOSIL studies, is continuing. This is in parallel to the number of commercial treatments utilising the device also continues to increase.

OncoSil Medical CEO & Managing Director Nigel Lange, said: *"We are thrilled to realise another important step in our development journey, with the 200th patient recently treated with the OncoSil™ device. This achievement represents yet another significant achievement in our commercialisation strategy. It importantly demonstrates that the OncoSil™ device is gaining traction as a treatment option for patients with unresectable, locally advanced pancreatic cancer. In another clear-cut positive, these treatments are occurring across an ever-widening geographic footprint as our strategy of penetrating multiple addressable markets across the globe continues to evolve."*

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	**Mr. Christian Dal Cin** CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival[1].

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (^{32}P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/